Formulary E-news :
Having trouble viewing this e-mail? Click here.
You are subscribed to %%list.name%% as %%emailaddr%%.
Unsubscribe from this list.
Formulary E-news
Modern Medicine Network
 
 
 
 
 
TOP SEARCHES: Clopidogrel // Rivaroxaban // Nebivolol
In this issue
Rivaroxaban in VTE
Psychotropics in children
Prasugrel and CYP
Osteoarthritis
Key Topic Updates

Survey

This month we would like to know...

Does your healthcare organization use mobile phone technologies, such as text messages, to try to improve medication adherence among patients?

Vote in our survey, and see what other P&T committee members have to say.
Click here to vote

Contact Us
Click here to contact a Formulary editor.

Click here to contact a Formulary sales representative.

Click here to learn about direct mail, reprints and classifieds in Formulary.

MAY 20, 2009
Rivaroxaban superior to enoxaparin in preventing VTE after knee arthroplasty
Results from the Regulation of Coagulation in Orthopaedic Surgery to Prevent Deep Vein Thrombosis and Pulmonary Embolism 4 (RECORD4) trial published in Lancet demonstrated that rivaroxaban 10 mg once daily is superior to subcutaneous (SC) enoxaparin in preventing venous thromboembolism (VTE) after total knee arthroplasty. More...
Serious ADRs associated with psychotropic use in children
Prescribing psychotropic medications for attention-deficit/hyperactivity disorder (ADHD) and other disorders in children is common around the world, even though serious adverse drug reactions (ADRs) have been reported with the use of these drugs, said speakers at the American College of Clinical Pharmacy (ACCP)/European Society for Clinical Pharmacy (ESCP) International Congress on Clinical Pharmacy meeting in Orlando, Florida. More...
Clinical outcomes with prasugrel not affected by cytochrome P450 genetic polymorphisms
An analysis published in Circulation demonstrated that the pharmacokinetic, pharmacodynamic, and clinical outcomes of prasugrel treatment are not affected by common functional cytochrome P450 (CYP) genetic variants, whereas clopidogrel treatment is affected by these genetic polymorphisms. More...
Osteoarthritis: A review of treatment options
Osteoarthritis (OA) is the most common form of arthritis and the leading cause of disability in the United States, especially among older adults. Treatment options have primarily focused on alleviating the pain often associated with this condition. Safety concerns over traditional pharmacotherapeutic agents used in the management of OA, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids, have led healthcare professionals to seek other options. This article reviews approaches to management of OA of the knee and hip. More...
2008 Top branded drugs by total prescriptions and total retail dollars
To see the top 100 drugs of 2008 by number of prescriptions written and total dollars spent, please click here.
Key Topic Updates
Medication Safety
New warnings added to erlotinib label
Warning about suicidal thoughts and actions added to antiepileptic drug labels
Boxed warning added to botulinum toxin labeling
Boxed warning added to labeling of testosterone gel products
PPIs linked to major heart risks in patients who undergo coronary stenting
Erythropoietin may worsen mortality in patients with cancer
Drug Pipeline/Clinical Updates
Web-based pharmacy care programs effective for hypertensive patients
Clinical judgment is best guide in determining appropriate medications for elderly patients
Drug-eluting stents may help prevent restenosis
Best practice evolving in hypertension treatment
24-day contraceptive regimen may be more effective
NSAID use inhibits postsurgery spine fusion
Regulatory/Legislative
Behind two Congressional health reform plans
Comparing Candidate Obama to President Obama
Video roundtable: The voice of healthcare professionals in the debate over healthcare reform
Comparative effectiveness research may shape treatment, coverage decisions

You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.